Core Viewpoint - The company has approved the establishment of a joint investment fund aimed at the pharmaceutical industry, with a total commitment of RMB 2 billion, to enhance its competitive edge in innovative sectors [1] Investment Fund Details - The investment fund, named "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)," will be co-established with Shanghai Fuguang Private Equity Fund Management Co., Ltd., Hangzhou Industrial Investment Co., Ltd., and Hangzhou Gongshu Industrial Fund Co., Ltd. [1] - The total subscribed capital of the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] Investment Focus - The fund will primarily invest in sectors such as innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other areas related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1] - The objective of the fund is to reduce the upfront costs associated with identifying and introducing high-quality innovative projects, diversify investment risks, and consolidate resources to strengthen the company's core competencies in key areas like innovative pharmaceuticals, medical aesthetics, and industrial microbiology [1]